We are live on
!
Find out more
TCM
Tekla Capital Management Portfolio holdings
AUM
$2.56B
1-Year Est. Return
18.15%
This Fund
S&P 500
This Quarter
Est. Return
+5.43%
1 Year Est. Return
+18.15%
3 Year Est. Return
+62.51%
5 Year Est. Return
+140.53%
10 Year Est. Return
+502.91%
AUM
$2.76B
AUM Growth
+$240M
(+9.5%)
Cap. Flow
+$114M
Cap. Flow
% of AUM
4.13%
Top 10 Holdings %
Top 10 Hldgs %
48.06%
Holding
144
New
27
Increased
15
Reduced
14
Closed
28
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Viatris
VTRS
|
+$58.4M |
| 2 |
Vertex Pharmaceuticals
VRTX
|
+$54.6M |
| 3 |
Johnson & Johnson
JNJ
|
+$45.1M |
| 4 |
Alkermes
ALKS
|
+$27.4M |
| 5 |
Teva Pharmaceuticals
TEVA
|
+$24.1M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
AbbVie
ABBV
|
+$72.5M |
| 2 |
Gilead Sciences
GILD
|
+$21.9M |
| 3 |
Perrigo
PRGO
|
+$21.6M |
| 4 |
GEVA
SYNAGEVA BIOPHARMA CORP COM STK (DE)
GEVA
|
+$19.4M |
| 5 |
Agios Pharmaceuticals
AGIO
|
+$9.46M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 84.12% |
| 2 | Real Estate | 3.08% |
| 3 | Financials | 1.53% |
| 4 | Technology | 0.04% |
| 5 | Industrials | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
26
CALL
Amgen
AMGN
$209B
| $22.4M | 0.81% |
+146,000
| New | +$23.4M |
|
27
Baxter International
BAX
$13.8B
| $22.4M | 0.81% |
588,384
| – | – |
|
28
Humana
HUM
$44B
| $21.4M | 0.78% |
+112,000
| New | +$20.8M |
|
29
iShares Biotechnology ETF
IBB
$9.52B
| $21.3M | 0.77% |
173,010
| – | – |
|
30
Jazz Pharmaceuticals
JAZZ
$16.2B
| $21.2M | 0.77% |
120,357
-384
| -0.3% | -$69K |
|
31
HCA Healthcare
HCA
$85.7B
| $19.4M | 0.7% |
213,788
+66,300
| +45% | +$5.31M |
|
32
Ventas
VTR
$44.7B
| $18.2M | 0.66% |
256,389
| – | – |
|
33
Neurocrine Biosciences
NBIX
$18.7B
| $18M | 0.65% |
375,860
-125,290
| -25% | -$5.31M |
|
|
PRTK
34
DELISTED
Paratek Pharmaceuticals, Inc.
PRTK
| $17.8M | 0.64% |
+691,000
| New | +$19.6M |
|
|
DOC
35
DELISTED
PHYSICIANS REALTY TRUST
DOC
| $16.1M | 0.58% |
1,050,902
| – | – |
|
|
IPXL
36
DELISTED
Impax Laboratories, Inc.
IPXL
| $15.8M | 0.57% |
344,683
| – | – |
|
|
ALR
37
DELISTED
Alere Inc
ALR
| $15.7M | 0.57% |
297,901
| – | – |
|
38
Acadia Pharmaceuticals
ACAD
$4.55B
| $15.5M | 0.56% |
+370,000
| New | +$14.3M |
|
39
McKesson
MCK
$101B
| $15.3M | 0.55% |
67,862
| – | – |
|
|
MPT
40
Medical Properties Trust
MPT
$2.81B
| $15.1M | 0.55% |
1,153,574
| – | – |
|
41
Omega Healthcare
OHI
$15B
| $14.2M | 0.51% |
413,116
| – | – |
|
42
Heron Therapeutics
HRTX
$94.1M
| $13.6M | 0.49% |
436,970
-436,970
| -50% | -$8.22M |
|
43
Community Health Systems
CYH
$391M
| $13.2M | 0.48% |
253,582
| – | – |
|
44
Karyopharm Therapeutics
KPTI
$159M
| $13M | 0.47% |
31,798
| – | – |
|
45
Alnylam Pharmaceuticals
ALNY
$27.4B
| $12.4M | 0.45% |
103,495
-26,700
| -21% | -$3.19M |
|
|
ESPR
46
CALL
DELISTED
Esperion Therapeutics
ESPR
| $12.1M | 0.44% |
+148,000
| New | +$14.5M |
|
|
ESPR
47
DELISTED
Esperion Therapeutics
ESPR
| $12.1M | 0.44% |
+148,000
| New | +$14.5M |
|
48
Cigna
CI
$76.1B
| $12M | 0.44% |
74,251
| – | – |
|
|
WELL.PRI
49
DELISTED
Welltower Inc.
WELL.PRI
| $11.9M | 0.43% |
200,000
| – | – |
|
50
Stryker
SYK
$133B
| $11.8M | 0.43% |
123,940
| – | – |
|
Similar funds
EST
VIA
AWS
JP
VCM
FCFS
FCB
BWM
Tekla Capital Management's Q2 2015 Portfolio in Review
As of Q2 2015, Tekla Capital Management held 144 positions worth $2.76B, up 9.5% from $2.52B the previous quarter. Its ten largest holdings account for 48% of the portfolio.
Tekla Capital Management deployed $114M of net new capital in Q2 2015, opening 27 new positions and adding to 15 existing holdings. Its largest new stake was Humana: 112,000 shares worth $21.4M.
By sector, the portfolio is most concentrated in Healthcare at 84% of assets, up from 80% a quarter earlier, followed by Real Estate and Financials.
On the sell side, the largest reduction was AbbVie, an estimated $72.5M trimmed.
- Tekla Capital Management's largest Q2 2015 buy was Humana: 112,000 shares worth $21.4M.
- Tekla Capital Management added most to Viatris in Q2 2015, an estimated $58.4M increase.
- Tekla Capital Management's biggest Q2 2015 reduction was AbbVie, cutting an estimated $72.5M.
- Tekla Capital Management fully exited Perrigo in Q2 2015, selling an estimated $21.6M.
- Tekla Capital Management's ten largest holdings make up 48% of its $2.76B portfolio in Q2 2015.
- Tekla Capital Management opened 27 new positions and closed 28 in Q2 2015.
- Tekla Capital Management's portfolio value rose 9.5% quarter-over-quarter to $2.76B.
Based on Tekla Capital Management's 13F filing for Q2 2015, filed 12 Aug 2015.